LBRX.US LB Pharmaceuticals Inc Common Stock
- Market cap
- USD 1.39B
- P/E
- -
- P/B
- 3.33x
- ROE
- -41.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LBRX.US undervalued?
Graham numberThe Graham number of LB Pharmaceuticals Inc Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LB Pharmaceuticals Inc Common Stock fundamental analysis
No fundamental analysis for LB Pharmaceuticals Inc Common Stock yet.
LB Pharmaceuticals Inc Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formula…
Full company profileLB Pharmaceuticals Inc Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LB Pharmaceuticals Inc Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -321K | - |
| Operating Income | -2.81M | -11.4M | -64.8M | -30.4M | -185M |
| EBITDA | -12.2M | -1.45M | -63.0M | -24.9M | -176M |
| Net Income | -14.3M | -6.28M | -63.1M | -25.2M | -173M |
| EPS | -4.05 | -1.77 | -18 | -1.00 | -5.23 |
| Balance Sheet | |||||
| Total Assets | 21.5M | 45.7M | 33.5M | 313M | 453M |
| Total Liabilities | 50.3M | 80.1M | 128M | 11.6M | 35.7M |
| Shareholders' Equity | -28.8M | -34.5M | -94.6M | 301M | 418M |
| Cash & Short-term Investments | 21.4M | 43.3M | 28.0M | 295M | 404M |
| Total Debt | 24.1M | - | 3.70M | 3.57M | 5.16M |
| Cash Flow | |||||
| Operating Cash Flow | -2.73M | -12.1M | -53.1M | -35.2M | -167M |
| Capital Expenditure | 0.00 | 25.0K | 769K | 52.0K | 620K |
| Free Cash Flow | -2.73M | -12.1M | -53.8M | -35.3M | -168M |
| Ratios | |||||
| ROE | - | - | - | -8.4% | -41.4% |
| ROA | -66.8% | -13.7% | -188.2% | -8.1% | -38.2% |
| Debt to Equity | - | - | - | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
LB Pharmaceuticals Inc Common Stock dividends
LB Pharmaceuticals Inc Common Stock has not paid dividends in the last 4 fiscal years.
Who owns LB Pharmaceuticals Inc Common Stock
- Insiders 0.92%
- Institutions 99.08%
- Public & others 0.00%
- Shares outstanding 32.4M
- Free float 26.6M
Top funds holding LBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 796K | 2.47% | +16.30% | Sep 2026 |
| iShares Russell 2000 ETF | 566K | 1.75% | 0.00% | Oct 2026 |
| JPMorgan Small Cap Growth A | 459K | 1.42% | -10.28% | Sep 2026 |
| JPM Global Healthcare C acc USD | 382K | 1.18% | -16.67% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 255K | 0.79% | -55.08% | Sep 2026 |
| Fidelity Small Cap Index | 245K | 0.76% | +0.21% | Aug 2026 |
| Fidelity Select Biotechnology | 236K | 0.73% | +25.89% | Aug 2026 |
| PGIM Jennison Health Sciences Z | 231K | 0.72% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Term Trust | 208K | 0.64% | 0.00% | Jun 2026 |
| Fidelity Growth Company Fund | 201K | 0.62% | 0.00% | Aug 2026 |
| T. Rowe Price Health Sciences | 198K | 0.61% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 184K | 0.57% | +156.11% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 167K | 0.52% | +2.88% | Oct 2026 |
| Calamos Timpani Small Cap Growth I | 146K | 0.45% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Blend A | 146K | 0.45% | -11.19% | Sep 2026 |
| T. Rowe Price New Horizons | 145K | 0.45% | -4.55% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 134K | 0.42% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 130K | 0.40% | +1.27% | Sep 2026 |
| Fidelity Extended Market Index | 114K | 0.35% | -4.73% | Sep 2026 |
| iShares Russell 2000 Value ETF | 112K | 0.35% | 0.00% | Oct 2026 |
Top institutions holding LBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.35M | 10.39% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.73M | 8.47% | +10.66% | Jun 2026 |
| RA Capital Management, LLC | 2.21M | 6.84% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 2.11M | 6.53% | +100.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.52M | 4.72% | +15.44% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.50M | 4.65% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.50M | 4.64% | +4.88% | Jun 2026 |
| TCG Crossover Management, LLC | 1.45M | 4.49% | -21.32% | Jun 2026 |
| Caligan Partners LP | 1.44M | 4.46% | 0.00% | Jun 2026 |
| Spruce Street Capital LP | 1.40M | 4.35% | +2.08% | Sep 2026 |
| Vanguard Capital Management, LLC | 971K | 3.01% | +8.55% | Jun 2026 |
| Balyasny Asset Management LLC | 921K | 2.86% | -0.24% | Jun 2026 |
| Alyeska Investment Group, L.P. | 864K | 2.68% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 800K | 2.48% | 0.00% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 631K | 1.95% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 613K | 1.90% | +18.25% | Jun 2026 |
| State Street Corp | 602K | 1.87% | +19.36% | Jun 2026 |
| Logos Global Management LP | 585K | 1.81% | -36.07% | Jun 2026 |
| The Goldman Sachs Group Inc | 576K | 1.79% | +58.45% | Jun 2026 |
| Jennison Associates LLC | 541K | 1.68% | +0.50% | Jun 2026 |
LB Pharmaceuticals Inc Common Stock company profile
- Company name
- LB Pharmaceuticals Inc Common Stock
- Ticker
- LBRX.US
- Exchange
- USA Stocks
- Listed since
- Sep 11, 2025
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 62
- Fiscal year end
- December
- Address
- One Pennsylvania Plaza, New York, NY, United States, 10119
- Phone
- 212 605 0300
- Website
- lbpharma.us
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
LB Pharmaceuticals Inc Common Stock management
10- Ms. Heather D. Turner Esq., J.D.CEO & Director · born 1973
- Mr. Gad SofferChief Operating & Business Officer · born 1977
- Mr. Joseph M. Miller CPAChief Financial Officer · born 1974
- Ms. Minako Pazdera J.D., Ph.D.General Counsel
- Ms. Lindsay BeaupreSenior VP of People & Culture
- Dr. Richard A. Silva Ph.D.Senior Vice President of Technical Operations · born 1968
- Dr. James Rawls Pharm.D.Senior Vice President of Regulatory Affairs
- Ms. Ellen RoseSenior Vice President of Corporate Affairs
- Ms. Kaya Pai Panandiker KamleshChief Commercial Officer · born 1977
- Mr. Christopher ZergebelSenior Vice President of Clinical Operations